Publications by authors named "Oliver Politz"

Claim this Profile
D
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, Annika Böhme, Ralf Lesche, Oliver Politz

Mol Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Oliver Politz

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.
Simon Heller, Sarah Glaeske, Katja Gluske, Juliane Paul, Annika Böhme, Oliver Politz

Clin Exp Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, Claudia Kamfenkel, Oliver Politz

Mol Cancer Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Fabio Raith, Daniel H O'Donovan, Clara Lemos, Oliver Politz, Bernard Haendler

Int J Mol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Konrad Klinghammer, Oliver Politz, Theresa Eder, Raik Otto, Jan-Dirk Raguse

Oncotarget· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Oliver Politz

Mol Cancer Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Dachuan Huang, Tammy Linlin Song, Maarja-Liisa Nairismägi, Yurike Laurensia, Wan-Lu Pang, Oliver Politz

Br J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, Oliver Politz

Blood Adv· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Sylvia Grünewald, Oliver Politz, Sebastian Bender, Mélanie Héroult, Klemens Lustig

Int J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Hung Huynh, Richard Ong, Kah Yong Goh, Liek Yeow Lee, Florian Puehler, Oliver Politz

Int J Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Oliver Politz, Franziska Siegel, Lars Bärfacker, Ulf Bömer, Andrea Hägebarth

Int J Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Marion Rudolph, Tobias Anzeneder, Anke Schulz, Georg Beckmann, Annette T Byrne, Oliver Politz

BMC Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Katharina C Kaehler, Oliver Politz, David Henderson, Hannes-Friedrich Ulbrich, Axel Hauschild

Melanoma Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
Sharon L Longo, David J Padalino, Sandra McGillis, Kirstin Petersen, Hartmut Schirok, Oliver Politz

Invest New Drugs· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Holger Hess-Stumpp, Tomke Ute Bracker, David Henderson, Oliver Politz

Int J Biochem Cell Biol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen receptor function is modulated by the tissue-specific AR45 variant.
Isabelle Ahrens-Fath, Oliver Politz, Christoph Geserick, Bernard Haendler

FEBS J· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues.
Oliver Politz, Alexei Gratchev, Peter A G McCourt, Kai Schledzewski, Pierre Guillot

Biochem J· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis